Scotland Unveils £21m Fund for Rare Diseases

A £21 million fund will been made available to pay for rare orphan drugs that are not currently recommended by the Scotland’s regulatory watchdog, the Scottish Medicines Consortium (SMC). The fund will launch in March, and run until April 2014.  It will help cover successful new Individual Patient Treatment Requests for drugs that target rare

Continue Reading

Amgen Partners with BIND in $180 Million Agreement

Amgen has joined up with Bind Biosciences to develop a kinase inhibitor nanomedicine for treating a variety of solid tumours. The agreement provides the US biotech major with access to the technology at BIND, who has developed “a new class of highly selective targeted and programmable therapeutics,” which they call Accurins.  The partners are planning

Continue Reading

Ulcerative Colitis Drug Market to Reach $3.7 Billion by 2021

Sales of medication to treat ulcerative colitis in seven key markets are expected to double over the next decade, reaching $3.7 billion by 2021, according new research. The rapid growth will be largely driven by two premium-priced tumour necrosis factor-alpha (TNF-alpha) inhibitors – Abbott/Eisai’s Humira and Janssen/Merck/Mitsubishi Tanabe’s Simponi – and two novel therapies –

Continue Reading

Study Finds Antibiotics Ineffective for Coughs

A recent study has found that the use of antibiotics to treat persistent coughs (not caused by pneumonia) is ineffective. The European study involved 2,061 patients with acute lower-respiratory-tract infections where pneumonia was not suspected, and the patients were randomised to receive either amoxicillin or a placebo. The findings showed that neither the duration of

Continue Reading

ACM Global Expand EU Lab Facilities

ACM Global Central Laboratory, the US-headquartered laboratory testing operation that raised its European profile in March 2009 by acquiring Pivotal Laboratories, have relocated their European laboratory to a bigger facility in York’s Hospital Fields Road. ACM Global confirmed that they have outgrown their prior facility in Aviator Court, York, which they have occupied since 1999.

Continue Reading

GW Pharmaceuticals Announces Mixed Results

GW Pharma has released mixed results for the year, with sales rising and profits decreasing, but the company continues to demonstrate potential in their R&D pipeline with inspiring data for a mid-stage, cannaboid-based diabetes drug. The organisation saw their sales for the year ending September 30, 2012, increase by £3.5 million to reach £33.1 million,

Continue Reading

Bayer Withdraws Schiff Bidding Interest

Bayer have declared that they are not going to follow plans to purchase American vitamins company, Schiff Nutrition International, four days after their $1.20 billion offer was beaten by Reckitt Benckiser. Roughly three weeks ago, Bayer announced a bid of $34 per share to acquire Schiff, but Reckitt since revealed an offer of $42.00 per

Continue Reading